Stocktoria
Protagonist Therapeutics, Inc PTGX
Protagonist Therapeutics, Inc (PTGX) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the safe zone. It does not currently pay a dividend. FY2025 revenue was $46.0M at a -282.8% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-05-06 | Citizens | Market Outperform (main) |
| 2026-05-06 | Wedbush | Outperform (main) |
| 2026-04-15 | Truist Securities | Buy (main) |
| 2026-04-07 | Clear Street | Buy (main) |
| 2026-03-19 | Leerink Partners | Outperform (main) |
| 2026-03-19 | JP Morgan | Overweight (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.796 |
| Retained earnings / assets | -0.704 |
| EBIT / assets | -0.237 |
| Equity / liabilities | 11.494 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| PTGX | Protagonist Therapeutics, Inc | 4/9 | 13.41 | — | -89.4% |
| SEPN | Septerna, Inc. | 4/9 | 3.75 | — | — |
| AQST | Aquestive Therapeutics, Inc. | 2/9 | -8.08 | — | -22.6% |
| CPIX | CUMBERLAND PHARMACEUTICALS INC | 4/9 | -0.86 | — | +17.6% |
| XLO | Xilio Therapeutics, Inc. | 4/9 | -6.58 | — | — |
| GOSS | Gossamer Bio, Inc. | — | — | — | -57.7% |
| WVE | Wave Life Sciences Ltd. | 2/9 | 1.15 | — | -60.5% |
About Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the natural hormone hepcidin in Phase 3 development for the treatment of the rare blood disorder polycythemia vera. The company is also developing PN-881, a potential best-in-class oral peptide IL-17 antagonist, for the treatment of immune-mediated skin diseases in Phase 1 clinical trials; PN-477 and PN-458, which are development candidates for the treatment of obesity; PN-8047, an orally administered hepcidin functional mimetic small molecule; L-4R alpha antagonist for the treatment of atopic dermatitis and moderate-to-severe asthma; and amylinR-based oral and subcutaneous mono- and poly-agonists for the treatment of obesity. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
FAQ
Is PTGX financially healthy?
Protagonist Therapeutics, Inc's Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does PTGX pay a dividend?
No, Protagonist Therapeutics, Inc does not currently pay a dividend.
How profitable is PTGX?
In FY2025, Protagonist Therapeutics, Inc had a net margin of -282.8% and a return on equity of -21.2%.
What is the analyst price target for PTGX?
The average Wall-Street price target for Protagonist Therapeutics, Inc is $118.69, about 21.9% below the recent price, from 13 analysts (consensus: strong buy).
Is PTGX a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Protagonist Therapeutics, Inc: a Piotroski F-score of 4/9, an Altman Z″ in the safe zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.